Direct costs to private insurers of diversion of medications for attention-deficit/hyperactivity disorder
Citation
Aldridge, A., Kroutil, L., Cowell, A., Reeves, D., & Van Brunt, D. (2011). Direct costs to private insurers of diversion of medications for attention-deficit/hyperactivity disorder. PharmacoEconomics, 29(7)(1170-7690), 621 - 635.